Abstract | OBJECTIVE: The objective of this article was to review existing data of melflufen ( Pepaxto) as an additional treatment option for heavily pretreated relapsed and refractory multiple myeloma. DATA SOURCES: STUDY SELECTION/DATA EXTRACTION: Clinical trials including melflufen in relapsed refractory multiple myeloma and trials related to safety and clinical pharmacology were included. DATA SYNTHESIS: RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE:
Melflufen in combination with dexamethasone is a reasonable option for patients with relapsed and refractory multiple myeloma who have received at least 4 previous lines of therapy and considered ineligible for autologous stem cell transplant. Further clinical utilization in earlier lines of therapy is under review, pending the in-depth safety analysis by the FDA. CONCLUSIONS:
|
Authors | Jeremiah K Jessee |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 56
Issue 8
Pg. 951-957
(08 2022)
ISSN: 1542-6270 [Electronic] United States |
PMID | 34963319
(Publication Type: Journal Article, Review)
|
Chemical References |
- Peptides
- melflufen
- Phenylalanine
- Dexamethasone
- Melphalan
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Dexamethasone
- Humans
- Melphalan
(adverse effects, analogs & derivatives)
- Multiple Myeloma
(drug therapy)
- Peptides
(therapeutic use)
- Phenylalanine
(analogs & derivatives)
|